Technology
Theme
AI infrastructure remained the dominant market narrative, but capital is rotating toward companies with measurable backlog, recurring revenue, and physical bottleneck exposure. Semiconductor equipment, networking, storage, cloud platforms, and cybersecurity all benefited, while richly valued names without fundamental confirmation remained vulnerable.
Movers
- NVDA(NVIDIA): Record revenue and earnings, a 70% forward-growth outlook, GPU price increases, and a major AWS deployment agreement reinforced NVIDIA’s position as the AI infrastructure standard. The critical risk is geopolitical: China is excluded from the growth outlook, increasing the incentive for a parallel Chinese ecosystem.
- AMAT(Applied Materials), KLAC(KLA), LRCX(Lam Research), MKSI(MKS Instruments), and ENTG(Entegris): Strong orders, advanced packaging demand, estimate upgrades, and rising fab utilization confirmed a broad semiconductor capital-spending cycle. The group is benefiting from AI demand beyond the headline GPU complex.
- AVGO(Broadcom), MRVL(Marvell Technology), ANET(Arista Networks), CSCO(Cisco), CRDO(Credo), ALAB(Astera Labs), COHR(Coherent), LITE(Lumentum), and GLW(Corning): Optical connectivity, custom silicon, switching, and liquid cooling are becoming the next AI infrastructure bottlenecks. Demand is structural, but valuations now require sustained hyperscaler spending and margin discipline.
- MU(Micron Technology), SNDK(Sandisk), STX(Seagate Technology), WDC(Western Digital), and RMBS(Rambus): Memory and storage companies reported exceptional demand visibility, including take-or-pay agreements, strong nearline orders, and rising AI data-center exposure. The market is treating memory as a strategic constraint rather than a normal commodity cycle.
- CRM(Salesforce), NOW(ServiceNow), VEEV(Veeva Systems), SNOW(Snowflake), MDB(MongoDB), SAP(SAP), and MSFT(Microsoft): Enterprise AI is moving from pilots into production. Agentforce, AI ACV, Falcon, native vector search, Joule, and Azure growth provided evidence that platforms with distribution and proprietary enterprise data are monetizing AI fastest.
- CRWD(CrowdStrike), OKTA(Okta), PANW(Palo Alto Networks), ZS(Zscaler), FTNT(Fortinet), RBRK(Rubrik), NET(Cloudflare), NTSK(Netskope), and SAIL(SailPoint): Cybersecurity re-rated as AI expands the attack surface. CrowdStrike’s record ARR and Okta’s profitability were the strongest read-throughs, although Okta’s declining billings and the group’s elevated multiples remain material risks.
- ORCL(Oracle), AMZN(Amazon), GOOGL(Alphabet), and META(Meta Platforms): Hyperscalers are committing extraordinary capital to AI compute. Oracle’s customer-funded infrastructure model and Alphabet’s profitable cloud growth are constructive; Meta’s 91% free-cash-flow collapse highlights the cost of scaling AI before monetization is proven.
- PATH(UiPath), PEGA(Pegasystems), U(Unity Software), TEAM(Atlassian), FIG(Figma), ADBE(Adobe), ADSK(Autodesk), and HUBS(HubSpot): Enterprise software rallied on the view that AI is an enabler rather than a disruptor. The move remains sentiment-heavy for UiPath, Pegasystems, and Atlassian; Figma has the clearest evidence of live AI usage and monetization.
- IBM(IBM), CTSH(Cognizant), ACN(Accenture), EPAM(EPAM), TYL(Tyler Technologies), IT(Gartner), INTU(Intuit), DOCU(DocuSign), WDAY(Workday), MANH(Manhattan Associates), and DT(Dynatrace): Services and workflow platforms are embedding AI into recurring enterprise operations. Accenture, Cognizant, and Gartner offer more tangible enterprise adoption than speculative AI infrastructure names, while Intuit’s weaker FY2027 outlook exposed a growth wall.
- AMD(Advanced Micro Devices), INTC(Intel), QCOM(Qualcomm), TXN(Texas Instruments), NXPI(NXP Semiconductors), STM(STMicroelectronics), MPWR(Monolithic Power Systems), MCHP(Microchip Technology), QRVO(Qorvo), SWKS(Skyworks Solutions), and LSCC(Lattice Semiconductor): The semiconductor rally broadened into analog, embedded, edge AI, automotive, and industrial applications. AMD and Intel combine strong strategic narratives with stretched valuations and execution risk, while Qorvo’s defense-led mix shift is a more tangible margin story.
- QNT(Quantinuum), IONQ(IonQ), and QBTS(D-Wave Quantum): Quantum computing remains a bifurcated trade. Quantinuum’s Oracle cloud deployment is the clearest commercialization milestone; IonQ’s SkyWater acquisition improves vertical integration, while D-Wave remains heavily dependent on future system sales and speculative valuation.
- SPCX(SpaceX), CBRS(Cerebras Systems), CRWV(CoreWeave), NBIS(Nebius), KEEL(Keel Infrastructure), IREN(IREN), APLD(Applied Digital), CORZ(Core Scientific), and HUT(Hut 8): AI data-center operators rallied on contracted power and GPU scarcity. Nebius and Cerebras have the strongest disclosed commercial visibility; Applied Digital, IREN, and Hut 8 remain high-beta thematic exposures without equivalent company-specific validation.
- AAPL(Apple): Apple’s leadership transition, on-device AI strategy, and potential foldable and wearable products make the company a test of whether privacy-centric AI can create a new hardware cycle. The stock’s premium valuation leaves little room for an underwhelming product event.
- HPQ(HP), DELL(Dell Technologies), and HPE(Hewlett Packard Enterprise): Dell and HPE benefited from AI server and networking demand, while HP’s revenue growth masked a collapse in Personal Systems margins. The market is rewarding infrastructure exposure but rejecting pricing-led PC growth without margin recovery.
Actionable Ideas (Positive)
- NVDA(NVIDIA): The AWS agreement, pricing power, and next-generation platform demand reinforce NVIDIA’s leadership. Buy on disciplined pullbacks; the key monitor is whether China exclusion begins to impair ecosystem breadth.
- AMAT(Applied Materials) and KLAC(KLA): Record orders, advanced packaging exposure, and long-duration service revenue support a bullish semiconductor-equipment thesis. Favor the equipment complex over late-cycle speculative GPU proxies.
- CRWD(CrowdStrike): Record net-new ARR and AI-driven security demand validate the platform model. Use as the sector quality leader, but size for valuation risk.
- VEEV(Veeva Systems) and NOW(ServiceNow): Falcon and AI ACV demonstrate production-level enterprise monetization. The actionable angle is long exposure to software platforms converting AI into recurring contract value rather than usage-driven hype.
- MU(Micron Technology): Take-or-pay commitments and sold-out HBM capacity materially reduce normal memory-cycle risk. Buy for structural HBM exposure, with delivery obligations and hyperscaler capex as the principal checks.
- ORCL(Oracle): Customer-funded GPU infrastructure and accelerating OCI growth offer a differentiated way to own the AI buildout. Prefer ORCL to capital-intensive neoclouds where revenue visibility depends on continuous external financing.
Actionable Ideas (Negative)
- META(Meta Platforms): The 91% free-cash-flow decline and massive AI capex program create a clear margin-risk setup. Fade rallies until AI monetization catches up with infrastructure spending.
- CRDO(Credo), COHR(Coherent), and LITE(Lumentum): Strong demand is offset by extreme multiples, customer concentration, and rising capital requirements. Avoid chasing; use earnings misses or ramp delays as short catalysts.
- PATH(UiPath) and PEGA(Pegasystems): The rally is primarily a read-through from Salesforce rather than company-specific execution. Short or hedge into the September earnings test if billings and guidance fail to validate the agentic-AI narrative.
- INTC(Intel): The strategic turnaround is credible, but the stock is pricing in near-perfect 18A and foundry execution. The risk/reward is asymmetric to the downside if process timelines slip.
Financials
Theme
Financials combined strong capital returns with a widening focus on digital infrastructure, private markets, and tokenized settlement. The sector’s central risk is not liquidity but valuation and credit quality, particularly where regulatory capital, CRE exposure, or consumer delinquencies are rising.
Movers
- JPM(JPMorgan Chase), BAC(Bank of America), TD(Toronto-Dominion Bank), RY(Royal Bank of Canada), CM(CIBC), BNS(Bank of Nova Scotia), FITB(Fifth Third Bancorp), and HBAN(Huntington Bancshares): Banks are expanding through AI efficiency, Texas branch buildouts, capital markets, and cross-border transaction banking. JPMorgan’s potential $13 billion capital-relief hit and TD’s planned reduction in CET1 to fund returns are the most important balance-sheet risks.
- COF(Capital One), AXP(American Express), MA(Mastercard), V(Visa), PYPL(PayPal), XYZ(Block), AFRM(Affirm), SOFI(SoFi), CHYM(Chime Financial), and HOOD(Robinhood): Payments and fintech are moving toward embedded finance, subscriptions, crypto rails, and tokenized assets. Affirm’s growth and tax benefit were strong, but Block’s stagnant Cash App users and PayPal’s branded-checkout margin pressure remain weaknesses.
- BLK(BlackRock), BX(Blackstone), APO(Apollo Global Management), KKR(KKR), BAM(Brookfield Asset Management), GS(Goldman Sachs), MS(Morgan Stanley), AMP(Ameriprise Financial), IVZ(Invesco), BEN(Franklin Templeton), TROW(T. Rowe Price), and PFG(Principal Financial): Asset managers are positioning themselves as financiers of AI infrastructure and private-market retirement products. BlackRock’s Bitcoin ETF inflows and the $500 billion AI-financing consortium are the clearest institutional signals.
- ACGL(Arch Capital), AFG(American Financial Group), AFL(Aflac), AIG(American International Group), ALL(Allstate), AIZ(Assurant), CB(Chubb), CINF(Cincinnati Financial), ERIE(Erie Indemnity), KNSL(Kinsale Capital), MKL(Markel), PGR(Progressive), TRV(Travelers), and UNM(Unum): Underwriting discipline and capital return remain powerful differentiators, but catastrophe losses, declining premiums, and stretched valuations are separating winners from laggards. Allstate, Arch, Travelers, and Kinsale showed operating strength; AIG, Aflac, Markel, and Unum showed deteriorating fundamentals.
- C(Citigroup), RF(Regions Financial), and WFC(Wells Fargo): These names lagged stronger peers as investors focused on tangible book value, CRE exposure, and the limited efficacy of Treasury bond buybacks. Cheap valuation alone is no longer sufficient without evidence of capital efficiency or asset-quality improvement.
- CME(CME Group), ICE(Intercontinental Exchange), NDAQ(Nasdaq), TW(Tradeweb), FMX(FMX), and MIAX(Miami International Holdings): Exchanges are expanding into retail derivatives, fraud intelligence, and tokenized settlement. Tradeweb’s onchain repo and Nasdaq’s Verafin integration are the most strategically important developments.
- COIN(Coinbase): The Bitcoin-backed conforming mortgage extends Coinbase’s role from exchange to digital-asset financial infrastructure. The $260 million waitlist validates demand, but regulatory and credit-cycle risks remain substantial.
- MCO(Moody’s), SPGI(S&P Global), FICO(Fair Isaac), and TRU(TransUnion): Credit analytics are becoming more valuable as AI infrastructure financing introduces balance-sheet opacity and consumer credit stress rises. S&P Global’s warning on hyperscaler cash flow is a significant systemic signal.
- FMCC(Freddie Mac), FNMA(Fannie Mae), RKT(Rocket Companies), and PAC(Pacific Alliance-style investment vehicle): Housing finance remains constrained by mortgage rates near 6.7%. Freddie and Fannie are supporting liquidity, while Rocket is trying to monetize a buyer-friendly housing market through its Redfin integration.
Actionable Ideas (Positive)
- ALL(Allstate): An 88.5 combined ratio, strong investment income, and a low forward multiple create a favorable risk/reward profile. Buy as the preferred value exposure among large P&C insurers.
- ACGL(Arch Capital): A 77.5 reinsurance combined ratio and aggressive buybacks show superior underwriting discipline. Accumulate on weakness while catastrophe losses remain contained.
- BLK(BlackRock): IBIT inflows, tokenized ETF infrastructure, and AI-financing exposure create multiple secular growth engines. Use as the highest-quality liquid expression of institutional crypto and AI infrastructure adoption.
- CME(CME Group) and TW(Tradeweb): Product expansion and onchain repo adoption can increase transaction volume and deepen network effects. Own for long-term capital-markets infrastructure exposure.
Actionable Ideas (Negative)
- RF(Regions Financial): The tangible-book miss and CRE exposure create a direct balance-sheet downside risk. Avoid regional-bank exposure until asset quality stabilizes.
- AIG(American International Group) and MKL(Markel): Shrinking premiums, weak book-value growth, and deteriorating margins undermine the low-multiple argument. Prefer better underwriting operators rather than buying the apparent discount.
- ARCC(Ares Capital): Rising non-accruals, declining NAV, and a dividend exceeding GAAP earnings point to distribution risk. Underweight high-yield BDC exposure ahead of a potential dividend reset.
Healthcare
Theme
Healthcare news favored companies with differentiated therapies, diagnostics, and recurring procedure revenue. The strongest catalysts were regulatory approvals and platform expansion; the principal risks were payer pressure, clinical setbacks, and margin dilution from aggressive growth.
Movers
- ABBV(AbbVie), AMGN(Amgen), GILD(Gilead Sciences), JNJ(Johnson & Johnson), LLY(Eli Lilly), MRK(Merck), PFE(Pfizer), NVO(Novo Nordisk), NVS(Novartis), REGN(Regeneron), RVMD(Revolution Medicines), and SMMT(Summit Therapeutics): Oncology, immunology, obesity care, and Alzheimer’s drove the sector. AbbVie’s subcutaneous Skyrizi filing, J&J’s IMAAVY approval, Revolution’s Rasonque approval, and Summit’s positive ivonescimab data were the most material catalysts. Novo remains the clear laggard as Lilly’s Zepbound cost data challenges its obesity franchise.
- RHHBY(Roche), BIIB(Biogen), and NVS(Novartis): FDA clearance of the Elecsys pTau217 test and at-home Lecanemab delivery reinforce the emerging diagnosis-to-treatment Alzheimer’s ecosystem.
- BSX(Boston Scientific), ABT(Abbott Laboratories), MDT(Medtronic), ISRG(Intuitive Surgical), GMED(Globus Medical), EW(Edwards Lifesciences), SYK(Stryker), TFX(Teleflex), PHG(Philips), and BDX(Becton Dickinson): Medical-device innovation remained strong, but Boston Scientific faces a damaging cyberattack and stagnation in FARAPULSE and WATCHMAN. Medtronic’s Bravo CF safety alert is a separate quality-control overhang.
- CNC(Centene), HUM(Humana), UNH(UnitedHealth), ELV(Elevance Health), CI(Cigna), MOH(Molina Healthcare), CVS(CVS Health), HCA(HCA Healthcare), and DVA(DaVita): Managed care is bifurcated between strong scale and rising medical-cost or regulatory risk. Centene produced the strongest earnings momentum; Molina and UnitedHealth face medical-cost pressure; proposed antitrust action directly threatens vertically integrated models.
- GH(Guardant Health), NTRA(Natera), VCYT(Veracyte), DGX(Quest Diagnostics), CRL(Charles River Laboratories), ILMN(Illumina), and WAT(Waters): Precision diagnostics and life-sciences tools continue to benefit from personalized medicine. Guardant’s patent judgment and 6% royalty create a major exception to the otherwise constructive diagnostics narrative.
- BTSG(BrightSpring), ENSG(Ensign Group), EHC(Encompass Health), THC(Tenet Healthcare), FMS(Fresenius Medical Care), and MEDP(Medpace): Home-based, post-acute, dialysis, and clinical-trial services are seeing durable demand, but labor costs, reimbursement dependence, and slowing CRO growth are becoming more important.
- TEM(Tempus AI) and CRSP(CRISPR Therapeutics): AI-enabled clinical decision-making and gene editing remain high-beta healthcare growth themes. Tempus’ ECG-PH clearance broadens its platform; CRISPR’s Ark ownership is a sentiment signal rather than a fundamental catalyst.
Actionable Ideas (Positive)
- LLY(Eli Lilly): Oncology growth, Alzheimer’s diagnostics, and evidence that Zepbound may reduce total healthcare costs strengthen the commercial thesis. Prefer LLY over NVO in obesity exposure.
- ABBV(AbbVie): Skyrizi and Rinvoq growth, a raised outlook, and the subcutaneous Crohn’s filing support durable franchise expansion. Buy for a combination of growth, dividend support, and regulatory optionality.
- RVMD(Revolution Medicines): Rasonque approval validates the RAS-targeted platform and creates a commercial oncology base. Own as a higher-risk oncology growth position, with payer adoption as the key milestone.
- ISRG(Intuitive Surgical): Record cash generation and robotics leadership make the stock’s selloff a contrarian setup. Accumulate selectively despite the premium multiple.
- NTRA(Natera): Clinical partnerships are expanding Signatera from a diagnostic into a biopharma-development platform. Buy for platform expansion, while monitoring reimbursement and regulatory adoption.
Actionable Ideas (Negative)
- NVO(Novo Nordisk): Weak Wegovy execution, CagriSema setbacks, and Lilly’s cost-saving evidence threaten market share and pricing power. Underweight or pair short NVO against long LLY.
- GH(Guardant Health): The $245 million judgment and ongoing 6% royalty structurally impair cash-flow economics. Avoid until the legal burden is resolved or valuation resets.
- BSX(Boston Scientific): Cybersecurity disruption and stalled flagship growth franchises undermine the premium-growth thesis. Avoid bottom-fishing until operational continuity and product growth are restored.
- MOH(Molina Healthcare): A 91.6% medical-cost ratio and sharp earnings decline make the valuation vulnerable. Stay underweight until margin recovery is visible.
Industrials
Theme
Industrials are being repriced around physical AI infrastructure, grid investment, defense modernization, and aerospace demand. Companies with backlog, self-performance, and pricing power are outperforming; those exposed to farm equipment, weak freight, or poor capital efficiency are lagging.
Movers
- PWR(Quanta Services), FIX(Comfort Systems USA), EME(EMCOR Group), ETN(Eaton), VRT(Vertiv), NVT(nVent Electric), HUBB(Hubbell), GNRC(Generac), CMI(Cummins), GEV(GE Vernova), TT(Trane Technologies), EMR(Emerson Electric), ROK(Rockwell Automation), FAST(Fastenal), and ITW(Illinois Tool Works): Data-center power, cooling, electrical construction, and automation generated the strongest industrial news flow. PWR and FIX have the clearest backlog-driven exposure; VRT and NVT offer direct thermal and power-management leverage.
- RTX(RTX), GE(GE Aerospace), HEI(HEICO), HWM(Howmet Aerospace), TDG(TransDigm), LMT(Lockheed Martin), NOC(Northrop Grumman), BA(Boeing), AVAV(AeroVironment), KTOS(Kratos Defense), TDY(Teledyne), BWXT(BWX Technologies), RDW(Redwire), and RKLB(Rocket Lab): Defense and aerospace demand remains strong, but execution quality is decisive. RTX, HEICO, and Northrop showed resilience; Boeing’s widened loss and cash decline were a sharp negative read-through.
- DE(Deere), AGCO(AGCO), CNH(CNH Industrial), VMI(Valmont Industries), CAT(Caterpillar), and TITN(Titan Machinery): Farm-equipment demand remains depressed by weak grower economics, high financing costs, and weather. Precision agriculture offers a long-term technology solution, but it is not yet offsetting the cyclical downturn.
- CLH(Clean Harbors), DCI(Donaldson), DOV(Dover), PH(Parker-Hannifin), SNA(Snap-on), NDSN(Nordson), CSL(Carlisle), FTV(Fortive), GGG(Graco), WAB(Wabtec), URI(United Rentals), CTAS(Cintas), and VLTO(Veralto): Execution remains uneven. Clean Harbors, ITW, Nordson, Cintas, and Veralto showed operating strength; Carlisle, Fortive, and Graco showed margin or capital-efficiency problems.
- DHI(D.R. Horton), PHM(PulteGroup), TOL(Toll Brothers), and NVR(NVR): Housing remains constrained by mortgage rates, but NVR’s land-light and mortgage-banking model offers the strongest downside protection. D.R. Horton and Pulte face affordability and litigation pressure.
- GFL(GFL Environmental), CMC(Commercial Metals), AVEX(AVEX Corp.), BAH(Booz Allen Hamilton), CACI(CACI International), BFAM(Bright Horizons), RHI(Robert Half), TBI(TrueBlue), PAYC(Paycom), and VOYG(Voyager Technologies): Government services and specialty business services benefited from defense and AI modernization, but several rallies lacked company-specific catalysts. Paycom and Robert Half showed the strongest earnings and cash-flow signals.
Actionable Ideas (Positive)
- PWR(Quanta Services): A $53.4 billion backlog and 41% revenue growth provide unmatched visibility into grid and data-center construction. Use as the core long-duration industrial AI-infrastructure position.
- FIX(Comfort Systems USA): Electrical revenue growth of 81% and a $10 billion-plus backlog show that the company is capturing the highest-growth portion of construction demand. Buy on pullbacks, but monitor acquisition-driven growth normalization.
- ETN(Eaton) and VRT(Vertiv): Power distribution, thermal management, and data-center backlogs are tangible beneficiaries of AI capex. Favor both over speculative data-center landlords.
- RTX(RTX): Margin expansion, F-35 work, and defense backlog provide a stronger earnings bridge than pure aerospace recovery stories. Accumulate for defense and aftermarket exposure.
- CLH(Clean Harbors): Pricing power, recurring hazardous-waste demand, and a 36% EPS increase support a high-quality industrial-services thesis. Buy for defensive growth.
Actionable Ideas (Negative)
- BA(Boeing): A wider loss, declining cash, and losses in both commercial and defense divisions show that backlog conversion remains unproven. **Avoid until delivery execution and cash generation improve.